Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,159
  • Shares Outstanding, K 76,311
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,560 K
  • 60-Month Beta 1.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.49
Trade ONCY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings $-0.07 on 08/01/24
  • Next Earnings Date 11/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9011 +3.21%
on 08/30/24
1.0200 -8.82%
on 09/05/24
-0.0279 (-2.91%)
since 08/16/24
3-Month
0.8500 +9.41%
on 08/13/24
1.1000 -15.45%
on 07/16/24
-0.0900 (-8.82%)
since 06/18/24
52-Week
0.8500 +9.41%
on 08/13/24
2.3000 -59.57%
on 09/27/23
-1.1100 (-54.41%)
since 09/18/23

Most Recent Stories

More News
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

ONCY : 0.9300 (-2.99%)
HALO : 62.31 (+0.61%)
CADL : 7.76 (+10.39%)
MRUS : 49.42 (-1.36%)
RHHBY : 39.6100 (+0.71%)
ONC.TO : 1.28 (-1.54%)
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
RHHBY : 39.6100 (+0.71%)
HALO : 62.31 (+0.61%)
CADL : 7.76 (+10.39%)
MRUS : 49.42 (-1.36%)
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
Cancer Rates Surge: Key Biotech Stocks Leading the Charge in Oncology Drug Development

USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
GSK : 42.43 (-0.31%)
GH : 25.08 (-0.04%)
EXEL : 26.82 (-2.83%)
GILD : 83.89 (+1.01%)
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
MBIO : 0.2539 (-5.26%)
LEGN : 49.91 (-2.46%)
JNJ : 166.15 (-0.55%)
NRIX : 24.74 (-0.36%)
Oncology Market Rising Towards $564.5B Amid Cancer Spike and Biotech Innovations

VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before....

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
MBIO : 0.2539 (-5.26%)
LEGN : 49.91 (-2.46%)
JNJ : 166.15 (-0.55%)
NRIX : 24.74 (-0.36%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.0102
2nd Resistance Point 0.9933
1st Resistance Point 0.9617
Last Price 0.9300
1st Support Level 0.9132
2nd Support Level 0.8963
3rd Support Level 0.8647

See More

52-Week High 2.3000
Fibonacci 61.8% 1.7461
Fibonacci 50% 1.5750
Fibonacci 38.2% 1.4039
Last Price 0.9300
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar